While biosimilars offer up to 90% savings over their specialty drug counterparts, uptake in the U.S. has been slow. PBIRx, a national leader in pharmacy benefit consulting and auditing, hosted an insightful webinar today, Biosimilars: The New Savings Frontier, providing actionable insights into the biosimilar market landscape, regulatory influences, and PBM strategies for plan sponsors.

The webinar featured a top panel of PBIRx pharmacists including Director of Clinical Consultants, Andrew Reis, RPh, MBA; Director of Strategic Accounts, Marc Shapiro, PharmD; and Clinical Pharmacy Consultant, Angela Medeiros, PharmD. The panel shared trends and tools to optimize biosimilar adoption to lower plan costs while supporting optimal health outcomes for members.

“Biosimilars offer tremendous cost savings potential but that potential is not being fully utilized,” said Patricia Sirowich, PBIRx President and Founder. “Today’s webinar is another example of how PBIRx partners with our clients to educate them on emerging drug trends, especially in regard to strategies around biosimilars that can counter the high-cost specialty drug trend.”

For more information about PBIRx’s prescription benefit consulting and auditing services or to receive a recording of the biosimilars webinar, email insight@pbirx.com.

About PBIRx

Founded in 1993, PBIRx provides independent pharmacy benefit auditing and consulting to employers and health plans. The firm holds SOC 2 Type 2 and SOC 3 attestation reports and has been recognized on the Inc. 5000 list of fastest-growing companies. More information is available at PBIRx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260604017792/en/

“Biosimilars offer tremendous cost savings potential but that potential is not being fully utilized,” said Patricia Sirowich, PBIRx President and Founder.